Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
<h4>Introduction</h4>CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0253176&type=printable |
| _version_ | 1826554638847967232 |
|---|---|
| author | Katsuhiro Yoshikawa Mitsuaki Ishida Hirotsugu Yanai Koji Tsuta Mitsugu Sekimoto Tomoharu Sugie |
| author_facet | Katsuhiro Yoshikawa Mitsuaki Ishida Hirotsugu Yanai Koji Tsuta Mitsugu Sekimoto Tomoharu Sugie |
| author_sort | Katsuhiro Yoshikawa |
| collection | DOAJ |
| description | <h4>Introduction</h4>CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail.<h4>Methods</h4>Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73-10 assays), was also examined.<h4>Results</h4>CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73-10 assay did not show a correlation (p = 0.115). Using the 73-10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively).<h4>Conclusions</h4>CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy. |
| first_indexed | 2024-12-14T17:05:38Z |
| format | Article |
| id | doaj.art-e1b61ea326794a06b2b5eb3adb0bcee7 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2025-03-14T07:44:06Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e1b61ea326794a06b2b5eb3adb0bcee72025-03-03T05:33:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01166e025317610.1371/journal.pone.0253176Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.Katsuhiro YoshikawaMitsuaki IshidaHirotsugu YanaiKoji TsutaMitsugu SekimotoTomoharu Sugie<h4>Introduction</h4>CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail.<h4>Methods</h4>Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73-10 assays), was also examined.<h4>Results</h4>CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73-10 assay did not show a correlation (p = 0.115). Using the 73-10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively).<h4>Conclusions</h4>CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0253176&type=printable |
| spellingShingle | Katsuhiro Yoshikawa Mitsuaki Ishida Hirotsugu Yanai Koji Tsuta Mitsugu Sekimoto Tomoharu Sugie Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients. PLoS ONE |
| title | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients. |
| title_full | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients. |
| title_fullStr | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients. |
| title_full_unstemmed | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients. |
| title_short | Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients. |
| title_sort | immunohistochemical analysis of cd155 expression in triple negative breast cancer patients |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0253176&type=printable |
| work_keys_str_mv | AT katsuhiroyoshikawa immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT mitsuakiishida immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT hirotsuguyanai immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT kojitsuta immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT mitsugusekimoto immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients AT tomoharusugie immunohistochemicalanalysisofcd155expressionintriplenegativebreastcancerpatients |